The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Laekna (2105.HK), a clinical-stage biotechnology company, announced reporting the results of a phase Ib study to evaluate the efficacy and.
For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit.
THURSDAY, Nov. 16, 2023 (HealthDay News) For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast Cancer Seventh International Consensus Conference, held from Nov. 9 to 11 in Lisbon, Portugal. Binghe Xu, M.D., from
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.